Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CDKN2A loss NRAS mut||melanoma||sensitive||Abemaciclib||Phase I||Actionable||In a Phase I trial, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383).||detail... 27217383|
|PubMed Id||Reference Title||Details|
|A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer||Full reference...|
|(27217383)||Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.||Full reference...|